Category: Keratoconus

Introduction to Keratoconus Keratoconus is a progressive eye condition that affects the shape of the cornea, the clear front surface of the eye. Keratoconus, once thought to be a rare disorder, has turned out to be relatively common. This disease can have a significant impact on a person’s vision and quality of life. Understanding the […]

Keratoconus is a progressive eye condition that affects the shape of the cornea, causing it to become thin and bulge out into a cone shape. This can result in various vision-related symptoms, including halos, glare, flares, smears, overlapping images, multiple images, streaking, and starbursts. While there is no cure for keratoconus, there are several strategies […]

Dr. Steven Greenstein, a prominent ophthalmologist at the Cornea and Laser Eye Institute, recently shared his remarkable findings on the 10-year follow-up for cornea cross linking and its outcomes at the ASCRS annual meeting. In a compelling interview with Ophthalmology Times, he provided valuable insights into his presentation titled “10-year Followup for Corneal Cross-linking and […]

Keratoconus is a progressive eye disorder that leads to the thinning and bulging of the cornea, resulting in distorted vision. Over the years, numerous modalities have emerged to improve the vision of affected patients, but the primary method for stabilizing the cornea remains corneal cross-linking (CXL). With the advent of cross-linking, it has become increasingly […]

On. August 18, 2021, Dr. Greenstein lectured to over 500 doctors on Corneal Inlays: “Past, Present, Future”

Steven A. Greenstein, MD https://www.healio.com/news/ophthalmology/20210111/corneal-tissue-addition-for-keratoconus-may-improve-visual-acuity-topography

The importance of early diagnosis of Keratoconus Peter S. Hersh MDCLEI Center for Keratoconus Dr. Hersh recently commented on an article that looked at referrals for newly diagnosed Keratoconus patients. This study of around 400 patients found that patients are first being diagnosed fairly late in the disease progression. This is important because, given the […]

A new treatment for keratoconus, called corneal collagen crosslinking (CXL), was approved by the U.S. Food and Drug Administration on April 18, 2016. The approval was granted to Avedro, Inc. for Photrexa Viscous, Photrexa and the KXL System. Collagen crosslinking uses a combination of riboflavin (a form of vitamin B2) and ultraviolet light. When use […]

At the CLEI Center for Keratoconus, Dr. Hersh and his staff are involved in a number of educational programs for keratoconus doctors and patients. In the Fall of 2012, we will sponsor our 8th Annual Keratoconus Patient Symposium in association with the National Keratoconus Foundation. In a very successful program last year, nearly 150 keratoconus […]